The joint venture aims to combine Skinvisible’s invisicare technology and a benzoyl peroxide (BPO) manufactured by Cambrex in a new line of over-the-counter acne formulations.
The agreement will involve a significant research and development project between the two companies, which will also see them sharing the marketing responsibilities for the new line.
Enhancing product development opportunities
“Our recent developments with Cambrex’s BPO in strengths of 2.5 percent, 5 percent, and 10 percent along with the BPO combination formulations we are developing, has given us a whole new series of acne products to license worldwide,” said Terry Howlett, president and CEO of Skinvisible.
“We have prove that we can control the release of active ingredient such as BPO with Invisicare and this can result in use of less active ingredient, less irritation, and better efficacy.”
Howlett also underlined the fact that the Invisicare technology enables the active ingredients to remain on the skin for longer periods of time, enhancing the effectiveness of the treatment.
Pharmaceutical, cosmeceutical and skin care
Skinvisible has focused its business on providing proprietary formulations for a wide range of pharmaceutical and cosmeceutical products, as well as providing a number of solutions for a range of skin care products.
Although benzoyl peroxide is a widely available chemical that has been used in acne treatments since the 1920s, Cambrex believes the quality of its formulation is reflected by the fact that it is made under cGMP and has a Drug Master File.
“This collaboration with Skinvisible will enable us to provide our clients with technology-enhanced delivery options for our BPO products,” said Steve Klosk, CEO of Cambrex.